Recorded Live May 15, 2014
Analysis of PRO Evidence for Orphan Drug Label Claims
In this webinar, we go over background information on orphan drugs, priority and standard reviews, PROs in rare diseases. Then, we analyze the results from reviewing product labels and drug approval packages (DAPs) for orphan drugs from January 2006. Our guest speaker is Ari Gnanasakthy.